Awareness program to expand distribution of Company's updates to retail and institutional investors
Toronto, Ontario--(Newsfile Corp. - April 2, 2019) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the
"Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software
solutions, announced that it will make its second issuance of shares under its online marketing and awareness program with AGORA
Internet Relations Corp. ("AGORACOM"). The Company previously announced the online marketing and awareness program in press
releases dated November 8, 2018 and December 13, 2018.
Under this second share issuance, the Company will issue 132,941 common shares of the Company ("Shares"), representing a
price of $0.085 per Share, for services valued at $10,000 plus 13% HST that were provided by AGORACOM during the second share
issuance period.
To learn more about CardioComm's products and for further updates regarding HeartCheck™ ECG device integrations please visit the
Company's websites at www.cardiocommsolutions.com and www.theheartcheck.com.
About AGORACOM
AGORACOM is the pioneer of online investor relations, online conferences and online marketing / branding services to North
American small and mid-cap public companies, with more than 250 companies served. More than just lip service, AGORACOM is the home
of more than 808K investors that visited 5.6 million times and read 52.4 million pages of information every year (Average 2008 -
2015).
AGORACOM traffic ranks within the top 0.5% of all websites around the world. These traffic results are independently tracked and
verified by Google analytics. AGORACOM traffic can be attributed to its strategy of maintaining the cleanest, moderated small-cap
discussion as a result of implementing the first ever Investor Controlled Stock Discussion Forums.
AGORACOM Founder, George Tsiolis, publishes the leading blog on small & mid cap investor relations. His 50 Small-Cap CEO Lessons
are a must read for CEO's looking to increase their education and knowledge about online investor relations.
About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing
electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an
external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 certification,
is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada).
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
egrima@cardiocommsolutions.com
investor.relations@cardiocommsolutions.com
Forward-looking statements
This release may contain certain forward-looking statements and forward-looking information with respect to the financial
condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm
Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on
information currently available to management. By their nature, forward-looking statements and forward-looking information involve
risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many
factors that could cause actual results and developments to differ materially from those expressed or implied by these
forward-looking statements and forward-looking information.
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking
information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information
contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National
Instrument 51-102 (Continuous Disclosure Obligations).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this release.
![Corporate Logo](https://orders.newsfilecorp.com/files/1775/43850_c407d948145dc980_logo.jpg)
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/43850